Followers | 46 |
Posts | 4502 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Tuesday, May 05, 2020 6:20:17 PM
By Carol E. Lee, Kristen Welker and Elyse Perlmutter-Gumbiner
WASHINGTON — There are 14 potential coronavirus vaccines under development as part of President Donald Trump's administration's program to fast-track one for use as early as January, senior administration officials tell NBC News.
That number was whittled down several weeks ago from 93 vaccines in development that were studied as part of the program, known as “Operation Warp Speed,” officials said.
Over the next two weeks, the 14 remaining vaccines will undergo additional testing and officials expect that anywhere from six to eight of them will make it to a subsequent round of clinical trials. Ultimately, the officials said, the goal is to have three or four vaccines make it through final testing and cleared for use early next year.
https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326
Recent ALT News
- Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology • GlobeNewswire Inc. • 07/25/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Altimmune to Participate at Leerink Partners Therapeutics Forum • GlobeNewswire Inc. • 07/02/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/23/2024 05:45:00 PM
- Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 08:45:00 PM
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/17/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/10/2024 09:45:00 AM
- Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/29/2024 11:31:00 AM
- Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 05/29/2024 09:45:00 AM
- Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) • PR Newswire (US) • 05/21/2024 01:00:00 PM
- The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT • PR Newswire (US) • 05/21/2024 09:45:00 AM
- Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) • PR Newswire (US) • 05/14/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm • PR Newswire (US) • 05/09/2024 09:51:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:04:51 AM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM